Flow Cytometry in Oncology and Immunology Market Report 2025

The flow cytometry in oncology and immunology market size has grown rapidly in recent years. It will grow from $2.11 billion in 2024 to $2.33 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to advancements in cancer research, immunology research growth, diagnostic applications, rise in autoimmune diseases, drug development and clinical trials.

The flow cytometry in oncology and immunology market size is expected to see rapid growth in the next few years. It will grow to $3.46 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to integration with genomics and proteomics, growing adoption of single-cell analysis, expanding applications in infectious diseases, rise in cancer incidence, and point-of-care flow cytometry. Major trends in the forecast period include immunophenotyping for immunotherapy, miniaturization of flow cytometry systems, multiparametric analysis, shift towards spectral flow cytometry, and collaborative research initiatives.

The anticipated rise in cancer prevalence is poised to drive the growth of flow cytometry in the oncology and immunology market. Cancer, a group of disorders characterized by uncontrolled cell growth, is a significant area of focus for flow cytometry in studying cancer and immune cells. For example, Macmillan Cancer Support reported in October 2022 that approximately 3 million people had cancer in 2020, and projections estimate an increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Hence, the increasing prevalence of cancer is a key factor propelling the growth of flow cytometry in the oncology and immunology markets.

The growing prevalence of HIV/AIDS is expected to contribute to the expansion of the flow cytometry market in oncology and immunology. HIV, a virus affecting the immune system, poses a global health challenge. Flow cytometry plays a crucial role in HIV/AIDS research and clinical applications by analyzing cells, especially immune cells, based on their physical and chemical properties. As of July 2023, the World Health Organization reported that approximately 39 million individuals were living with HIV in 2022, with an estimated range of 33.1 to 45.7 million. During the same period, around 630,000 people died due to HIV-related causes, with a confidence interval of 480,000 to 880,000. Moreover, approximately 1.3 million people contracted HIV in 2022, with a range of 1 to 1.7 million. Thus, the rising prevalence of HIV/AIDS is a significant driver for the growth of flow cytometry in the oncology and immunology market.

Technological advancements stand out as a prominent trend gaining traction in the flow cytometry market for oncology and immunology. Major players in this market are actively embracing innovative technologies to solidify their market positions. For example, in September 2022, Becton Dickinson and Company, a US-based medical technology provider, introduced the BD Research Cloud tailored for flow cytometry applications in oncology and immunology. This cloud-based software simplifies the flow cytometry process for researchers in fields such as immunology, virology, infectious disease, and oncology surveillance. Leveraging technologies such as BD Horizon RealYellow and RealBlue Reagents, along with the BD FACSDiscover S8 Cell Sorter featuring BD CellView Image Technology, BD aims to enhance flow cytometry capabilities, enabling researchers to optimize and advance their studies. BD Research Cloud, built on an industry-standard cloud infrastructure, is designed to complement BD equipment and reagents.

Companies in the flow cytometry market for oncology and immunology are also concentrating on innovative solutions such as automated sample preparation systems. An automated sample preparation system streamlines and automates various steps involved in preparing samples for analysis. For instance, in March 2022, Beckman Coulter Life Sciences, a US-based life science company, unveiled 'CellMek SPS,' a fully automated sample preparation system designed for clinical flow cytometry. This system offers on-demand processing for diverse sample types, enabling laboratories to expand their capabilities. CellMek SPS, building on a robust history of lab automation, integrates features that enhance efficiency by automating outdated manual preparation methods. This innovative system ensures a seamless workflow, delivering a continuous output of samples ready for analysis with complete traceability.

In February 2022, Becton, Dickinson and Company, a US-based medical technology firm, acquired Cytognos S.L. for an undisclosed sum. This acquisition aims to improve chronic disease management by expanding its range of blood cancer diagnostics, immune assessment tests, and informatics. The focus is on addressing the needs of patients, clinicians, and care providers to enhance understanding of the immune system, immune response, and minimal residual disease. Cytognos S.L. is a Spanish company that specializes in flow cytometry solutions for diagnosing blood cancer.

Major companies operating in the flow cytometry in oncology and immunology market include Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Becton Dickinson and Company, Laboratory Corporation of America Holdings, Agilent Technologies Inc., Sartorius AG, Beckman Coulter Inc., Bio-Rad Laboratories Inc., Sysmex Partec GmbH, OPKO Health Inc., Miltenyi Biotec, NeoGenomics Laboratories Inc., Luminex Corporation, Q2 Solutions LLC, DiaSorin S.p.A, BioLegend Inc., Cytek Biosciences Inc., Cell Signaling Technology Inc., Standard BioTools Inc., Sony Biotechnology Inc., NanoCellect Biomedical Inc., Nexcelom Bioscience LLC, CytoReason.

North America was the largest region in the flow cytometry in oncology and immunology market in 2024. The regions covered in the flow cytometry in oncology and immunology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the flow cytometry in oncology and immunology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Flow cytometry is an advanced analytical technique widely used in oncology and immunology to assess the physical and chemical properties of cells or particles as they pass through a fluid stream and a laser beam. This technology allows for the simultaneous measurement of various cellular parameters, including size, granularity, and the expression of surface and intracellular markers. This capability enhances the study of cell populations and their functions in both health and disease.

The primary categories of flow cytometry in oncology and immunology encompass immunology and oncology. Immunology, a field within biomedical science, explores the immune system and its reactions to foreign substances referred to as antigens. Within the realms of oncology and immunology, flow cytometry involves diverse technologies, including cell-based flow cytometry and bead-based flow cytometry. These technologies find applications in various contexts such as translational research and clinical research. The end users of flow cytometry in this context encompass hospitals, diagnostic laboratories, reference laboratories, pharmaceutical and biotechnology companies, academic research institutes, contract research organizations, among others.

The flow cytometry in oncology and immunology research report is one of a series of new reports that provides flow cytometry in oncology and immunology market statistics, including the flow cytometry in oncology and immunology industry's global market size, regional shares, competitors with flow cytometry in oncology and immunology market share, detailed flow cytometry in oncology and immunology market segments, market trends and opportunities, and any further data you may need to thrive in the flow cytometry in oncology and immunology industry. This flow cytometry in oncology and immunology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The flow cytometry in oncology and immunology market includes revenues earned by entities by providing services such as cell-based assay services, drug development services, and minimal residual disease (MRD) monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The flow cytometry in oncology and immunology market also consists of sales of products flow cytometers, fluorescence-activated cell sorters (FACS), monoclonal antibodies, and fluorochromes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.